Micropos introduces RayPilot® HypoCath™, electromagnetic tumor tracking without surgical intervention at ESTRO
Micropos Medical is proud to announce the launch of RayPilot® HypoCath™, a new member of the RayPilot family, at the ESTRO congress in Barcelona.
Welcome to visit the Micropos Booth 5200 to learn more.
RayPilot HypoCath provides high precision electromagnetic prostate tracking without surgical intervention.
HypoCath is designed like an ordinary Foley catheter with integrated RayPilot transmitter technology, giving the clinicians a unique tool with real time tracking of both the prostate region and the urethra with sub-millimeter accuracy. Tumor localisation as well as urethral tracking is essential when increasing doses in hypofractionated/SBRT prostate cancer protocols.
The application of the RayPilot HypoCath is fast and simple, according to the standard of care procedure for ordinary urinary catheters. Once in place patient set-up is performed with conventional image technology (kV/CBCT) and the RayPilot software starts tracking the ROI immediately in order to make sure that no motion occur from the moment of image acquisition nor during the treatment. If motion exceeds predefined margins RayPilot software gives manual or automatic warnings for gating of the beam. The RayPilot HypoCath remains throughout all sessions and is removed easily after the final fraction.
RayPilot HypoCath fits directly with current RayPilot receiving system and software and will be available after CE-marking in parallell to the original RayPilot Transmitter which has been in clinical use since 2010 and in extreme hypofractionated protocols since 2015.
Potential benefits of the RayPilot HypoCath include:
– Non-ionizing electromagnetic tracking of prostate and urethra
– Easy urinary catheter procedure
– Remains throughout all sessions and completely removed afterwards
– Reproducibility of bladder filling
– Fits in normal IGRT-workflow
All in all, Micropos Medical takes the ease of use of precise real time tracking to an unprecedented level of clinical desirability.
For additional information:
Tomas Gustafsson, CEO, Micropos Medical AB (publ), +46-31-760 80 05
About Micropos Medical AB (publ):
Micropos Medical AB (publ) (www.micropos.se) is a Swedish company that has developed the RayPilot® system, which is an electromagnetic real time tumor tracking system to be used with any linear accelerator. A precise and safe localization of the tumor can dramatically improve the outcome of the treatment, particularly for hypofractionated protocols. The RayPilot® system consists mainly of three parts; one transmitter that is placed close by the tumor, a receiving system that is placed directly on the treatment couchtop and software that continuously shows the precise tumor location, and hence where to focus the linac beam. RayPilot® has a unique gating solution qualified and compatible for use with Varian’s Clinac® iX linear accelerators and Trilogy® systems. Micropos develops an upcoming RayPilot® transmitter for positioning, in-situ dosimetry and automatic patient identification. RayPilot® is CE certified for prostate and surface use. Follow us on Facebook, www.facebook.com/MicroposMedical. The Micropos share is traded under the stock ticker MPOS. Not available for sale within the USA.